Dublin, Dec. 15, 2016 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Biochips and Microarrays - Technologies, Markets and Companies" to their offering.
This report is an analysis of biochip/microarray markets based on technologies and applications. The report starts with a description of technologies as a basis for estimation of markets. Technologies include array comparative genomic hybridization (CGH), copy number variation (CNV), DNA methylation, ChIP-Chip, RNA splice variants, and microRNA. Separate chapters are devoted to protein biochips/microarrays, microfluidics and nanobiotechnology-based nano-arrays.
Various applications of biochips and microarrays are described throughout the report. Areas of application such as point-of-care, genetic screening, cancer, and diagnosis of infections are included. Separate chapters are devoted to applications in drug discovery and development as well as personalized medicine
The report provides current share of each segment: market size in 2015 and projected value for the years 2020 and 2025. Gene expression has the largest share and is an established market. Share of microarray technologies in other areas will grow with the maximum growth in RNA splice variants followed by epigenetics. The growth in protein microarrays is somewhat less, partly because it is more mature than the other submarkets and has already shown considerable growth in the past. Impact of next generation sequencing on segments of microarray markets is identified. Customer requirements and unmet needs are described. Markets are also analyzed according to geographical areas.
Brief profiles of companies involved in biochip/microarray technologies are provided. Currently selected 92 companies are included along with listing of 120 collaborations between companies. The text is supplemented by 21 tables, 11 figures and 140 references to literature.
Key Topics Covered:
Executive Summary
1. Introduction
2. Biochip and Microarray Technologies
3. Microfluidics-based Biochips and Microarrays
4. Protein Biochips
5. Nanobiotechnology-based Biochips & Microarrays
6. Biochips & Microarrays for Epigenetics
7. Applications of Microarrays in Drug Discovery & Development
8. Biochips for Biomarkers, Molecular Diagnostics & Personalized
9. Markets
10. Companies
11. References
For more information about this report visit http://www.researchandmarkets.com/research/9rp3gn/biochips_and
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biotechnology


Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
First Western Ship Transits Strait of Hormuz Since Iran War Began
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Apple Turns 50: From Garage Startup to AI Crossroads
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 



